Reality Check

MMIT Reality Check on Bipolar Disorder (July 2021)

According to our recent payer coverage analysis for bipolar disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this ne...
0 Comments

MMIT Reality Check on Psoriatic Arthritis (July 2021)

According to our recent payer coverage analysis for psoriatic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this...
0 Comments

MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2021)

According to our recent payer coverage analysis for acute lymphoblastic leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sens...
0 Comments

MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2021)

According to our recent payer coverage analysis for hemophilia A or B with inhibitors treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make...
0 Comments

MMIT Reality Check on Type 2 Diabetes (SGLT2 and Combo) (Jun 2021)

According to our recent payer coverage analysis for type 2 Diabetes (SGLT2 and Combo) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make...
0 Comments

MMIT Reality Check on Urothelial/Bladder Cancer (Jun 2021)

According to our recent payer coverage analysis for urothelial/bladder cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense o...
0 Comments

MMIT Reality Check on Chemotherapy-Induced Nausea and Vomiting (June 2021)

According to our recent payer coverage analysis for chemotherapy-induced nausea and vomiting (CINV) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. ...
0 Comments

MMIT Reality Check on Hereditary Angioedema (June 2021)

According to our recent payer coverage analysis for hereditary angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense...
0 Comments

MMIT Reality Check on Non-Small Cell Lung Cancer BRAF+ (May 2021)

According to our recent payer coverage analysis for non-small cell lung cancer BRAF+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make ...
0 Comments

MMIT Reality Check on Cervical Cancer (May 2021)

According to our recent payer coverage analysis for cervical cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new...
0 Comments